Cogora: The Agency – August digest
The month of August has shown no let-up in the extent to which Cogora: The Agency are supporting our pharmaceutical and med tech clients.
Cogora: The Agency has been commissioned to execute a research programme designed to provide strategic insights into the use of and opportunities for unit-dose dispensing systems across sales channels within relevant markets in Europe. Phase 1 involved market analysis and prioritisation of target geographies and channels. Phase 2 – insight gathering – will kick off immediately, and consist of 21 Focus Groups of representative key players. Before the end of the year, the programme will culminate in data analysis and strategic recommendations (Phase 3).
Extending its portfolio of projects undertaken for Rare Disease companies, Cogora: The Agency has turned its attention to MLD (metachromatic leukodystrophy), a rare inherited deficiency that causes progressive neurological decline. There is a treatment, but it is only effective if introduced before there are neurological symptoms. While there is evidence that gall bladder abnormalities might be a red flag for the early diagnosis of MLD, the key is that it be picked up early in the paediatric population. The Agency has been interviewing a multidisciplinary team comprising paediatric gastroenterologists, paediatric neurologists, radiologists, hepatologists, oncologists and surgeons in preparation for a Nominal Group Technique meeting to deliver a protocol for early diagnosis of MLD, to be followed by publication in the peer-reviewed literature.
Earlier this year, Cogora: The Agency played a pivotal role in convening an advisory board comprising patients afflicted by chronic insomnia. One of the initiatives spun out of that activity has come to fruition, with Phase 1 of a Patient Advocacy Programme, to run to the end of 2025, with further developments being planned for 2026. It is the intention of the client that the programme be executed in the medium-to long term: it goes without saying that The Agency is excited about playing a part in this highly significant endeavour.
The Agency has also been flexing its arm at running a UK real-world service improvement audit of transperineal prostate biopsies, with the help of Consultant Urology Surgeons, Consultant Interventional Radiologists and Urology Nurse Specialists. The manuscript of our findings is due for submission to a peer-review journal.
And to cap off the month, the most recent of our engagements with our longstanding team of vascular access experts has resulted in the development of a series of podcasts capturing their tips and tricks for overcoming challenges in the selection and management of vascular access processes.
Check out what the team were up to in July for more examples of how Cogora: The Agency delivers consistent value for its clients. For more information, please contact us.